Levi & Korsinsky, LLP announces that a FIXX class action lawsuit has been filed on behalf of investors who purchased Homology Medicines, Inc. (FIXX) securities between June 10, 2019, and February 18, 2022 For more on the FIXX Lawsuit please contact us today.  

According to the Homology lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE FIXX CLASS ACTION LAWSUIT, CLICK HERE 

If you suffered a loss in Homology you have until May 24, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. 

CONTACT: 

Levi & Korsinsky, LLP 

Joseph E. Levi, Esq. 

55 Broadway, 10th Floor 

New York, NY 10006 

jlevi@levikorsinsky.com 

Tel: (212) 363-7500 

Fax: (212) 363-7171 

www.zlk.com